Concepedia

Phenotypic Screening Analysis

Phenotypic Screening Analysis is a computational method in drug repurposing research that identifies potential therapeutic indications by analyzing observable biological responses of cells or organisms to chemical compounds, distinguishing it from target-based approaches through its focus on phenotypic outcomes rather than predefined molecular targets.

193

Publications

9.1K

Citations

1.6K

Authors

522

Institutions

Publications per year

2017–2026

79

Parents

Publications

193

Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar–coding strategy

Daniel Shoemaker, Deval Lashkari, Don Morris et al. · Nature Genetics · 1996 · 569 citations

, , +12

The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases

Thomas Spangenberg, Jeremy N. Burrows, Paul Kowalczyk et al. · PLoS ONE · 2013 · 339 citations · Full text

, , +17

Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains

Chun‐wa Chung, Hervé Coste, Julia H. White et al. · Journal of Medicinal Chemistry · 2011 · 335 citations · Full text

, , +17

Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling

Mathias J. Wawer, Kejie Li, Sigrun Gustafsdottir et al. · Proceedings of the National Academy of Sciences · 2014 · 225 citations · Full text

, , +17

A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing

Thai-Hoang Pham, Yue Qiu, Jucheng Zeng et al. · Nature Machine Intelligence · 2021 · 223 citations · Full text

, , +16

1–5 of 193

Authors

1.6K

  1. SL
    Stuart L. Schreiber

    Harvard University, United States

    3 publications · 328 citations

    3

    h-index

  2. ZW
    Zhanguo Wang

    Roche (China), China

    3 publications · 179 citations

    3

    h-index

  3. OE
    Ola Engkvist

    AstraZeneca (Sweden), Sweden

    3 publications · 153 citations

    3

    h-index

  4. NF
    Natalie Franklin

    GlaxoSmithKline (United Kingdom), United Kingdom

    3 publications · 58 citations

    3

    h-index

  5. KD
    Kevin D. Read

    University of Dundee, United Kingdom

    3 publications · 123 citations

    3

    h-index

1–5 of 1.6K

Institutions

522

  1. Eli Lilly (United States)

    Indianapolis, United States

    6 h-index

    24 publications

    485 citations

  2. Inserm

    Paris, France

    5 h-index

    29 publications

    404 citations

  3. University of Dundee

    Dundee, United Kingdom

    5 h-index

    56 publications

    1.9K citations

  4. AstraZeneca (Sweden)

    Södertälje, Sweden

    5 h-index

    33 publications

    1.4K citations

  5. GlaxoSmithKline (United Kingdom)

    London, United Kingdom

    5 h-index

    27 publications

    5.2K citations

  6. National Institutes of Health

    Bethesda, United States

    4 h-index

    26 publications

    1K citations

  7. Harvard University

    Cambridge, United States

    4 h-index

    16 publications

    409 citations

  8. Centre National de la Recherche Scientifique

    Paris, France

    4 h-index

    14 publications

    398 citations

1–8 of 522

Venues

  1. PLoS ONE

    13 publications · 750 citations

    12

    h-index

  2. Journal of Medicinal Chemistry

    9 publications · 727 citations

    9

    h-index

  3. SLAS DISCOVERY

    7 publications · 235 citations

    7

    h-index

  4. PubMed

    Repository · 6 publications · 154 citations

    6

    h-index

  5. Applied and Environmental Microbiology

    AEM · 4 publications · 361 citations

    4

    h-index

1–5